Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Bevacizumab with TNT for Locally Advanced Rectal Cancer
NCT07134101Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of bevacizumab, serplulimab in rectal cancer, sponsored by Jiangsu Provincial People's Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
bevacizumabserplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07134101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134101.